Abstract
hierarchical clustering, 16 samples were classified as sensitive and 31 as resistant to Pemetrexed. Conclusions: The specificity of our microarray screen is 76% and 84% respectively, for sensitive and resistant samples, indicating that is a valid model to correctly classify the response to Pemetrexed in NSCLC surgical samples based upon gene profile analysis. This strategy would be adequate for predicting outcome of treatment of NSCLC patients with Pemetrexed
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
